Guideline on Virus Safety Evaluation of Biotechnological Investigational Medicinal Products

July 10, 2006

London, 07 Jul 2006

Full text



The purpose of this document is to provide scientific guidance relating to the viral safety of biotechnological medicinal products used in clinical trials. Guidance is provided with respect to:

  • the criteria for and the extent of viral safety evaluation studies, especially validation studies, that are required prior to and during clinical development.

  • the extent to which manufacturers are able to refer to in-house experience concerning virus safety evaluation.

  • the risk assessment which should form part of the safety evaluation.


    Full text

    European Agency for the Evaluation of Medicinal Products - EMEA

  • You've reached your article limit.

    Register to continue

    Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

    • Sign up for the editor's highlights
    • Receive World University Rankings news first
    • Get job alerts, shortlist jobs and save job searches
    • Participate in reader discussions and post comments

    Have your say

    Log in or register to post comments

    Most Commented

    James Fryer illustration (27 July 2017)

    It is not Luddism to be cautious about destroying an academic publishing industry that has served us well, says Marilyn Deegan

    Jeffrey Beall, associate professor and librarian at the University of Colorado Denver

    Creator of controversial predatory journals blacklist says some peers are failing to warn of dangers of disreputable publishers

    Hand squeezing stress ball
    Working 55 hours per week, the loss of research periods, slashed pensions, increased bureaucracy, tiny budgets and declining standards have finally forced Michael Edwards out
    Kayaker and jet skiiers

    Nazima Kadir’s social circle reveals a range of alternative careers for would-be scholars, and often with better rewards than academia

    hole in ground

    ‘Drastic action’ required to fix multibillion-pound shortfall in Universities Superannuation Scheme, expert warns